<DOC>
	<DOCNO>NCT01424423</DOCNO>
	<brief_summary>The drug test study GSK1223249 . The drug work inhibit protein prevents nerve growth . The trial expect involve approximately 36 patient . The study objective investigate tolerability , safety way body handle GSK1223249 range single dose patient Multiple Sclerosis ( MS ) .</brief_summary>
	<brief_title>NOGO-A Multiple Sclerosis FTIH</brief_title>
	<detailed_description>This phase I study GSK1223249 . The study design randomize , placebo-controlled , double-blind , sequential dose escalation , single dose administration . Approximately 36 patient relapse form Multiple Sclerosis ( least two relapse previous 24 month , OR least one relapse within last 12 month , OR least one document gadolinium-enhancing lesion brain magnetic resonance imaging ( MRI ) within 12 month prior Screening ) enrol .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<criteria>Suitable determine Principal Investigator , base his/her overall evaluation . A patient clinical abnormality laboratory parameter outside reference range population study may include Investigator GSK Medical Monitor agree find unlikely introduce additional risk factor interfere study procedure . Diagnosed relapse form MS define either Relapsing Remitting MS accord revise McDonald Criteria [ McDonald , 2001 ; Polman , 2005 ] plus one following : Occurrence least one relapse previous 12 month OR least 2 relapse previous 24 month OR least one document Gdenhancing lesion magnetic resonance imaging ( MRI ) within 12 month prior screen . OR Secondary Progressive MS , plus one following : Occurrence least one relapse previous 12 month OR least 2 relapse previous 24 month OR least one document Gdenhancing lesion magnetic resonance imaging ( MRI ) within 12 month prior screen . Expanded Disability Status Scale ( EDSS ) score ≤5.5 Male female 18 55 year age inclusive , time signing informed consent . Abnormal baseline blood test Treatment interferonbeta1b ( Betaferon ) , interferonbeta1a ( Rebif Avonex ) , glatiramer acetate ( Copaxone ) within 90 day dose . Treatment methylprednisolone systemic steroid within 60 day dose . Treatment within past 12 month currently follow agent : cyclosporine , azathioprine , methotrexate , cladribine , natalizumab ( Tysabri® ) monoclonal antibody , murine protein , Tcell vaccination , plasmapheresis , IVI gG , , stem cell transplantation . History intolerance acetominophen , ibuprofen , naproxen nonsteroidal antiinflammatory agent would preclude use least one study . Previous history anaphylaxis , severe allergic reaction , hypersensitivity albumin proteinbased therapeutic , include natalizumab ( Tysabri ) monoclonal antibody . History hypersensitivity component formulation . A positive prestudy Hepatitis B surface antigen positive Hepatitis C antibody result . Patients evidence dementia psychiatric illness , Investigator 's opinion , likely prevent full understanding and/or compliance study requirement procedure .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>September 2011</verification_date>
	<keyword>Safety</keyword>
	<keyword>GSK1223249</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Single dose escalation</keyword>
	<keyword>anti-GSK1223249 antibody</keyword>
	<keyword>Multiple Sclerosis</keyword>
</DOC>